JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
National Institutes of Health · National Institute of Arthritis and Musculoskeletal and Skin Diseases
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,199
total citations
- FWCI
- 37.42
- Percentile
- 100%
- References
- 197
Citations per year
Authors
6- DMDaniella M. SchwartzCorresponding
National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases
- YKYuka Kanno
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
- AVAlejandro V. Villarino
National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases
- MMMichael M. Ward
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
- MGMassimo Gadina
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
Topics & keywords
Topics
Keywords
- Janus kinase
- Immune system
- Medicine
- Psoriasis
- Inflammation
- Clinical trial
- Tofacitinib
- Rheumatoid arthritis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.